Avicin Therapeutics Ltd is categorized under Commercial Biotechnical Research in Durham, NC and active since 2013.
Avicin Therapeutics Ltd was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Daniel Cato at the company’s single location by writing to 4364 South Alston Avenue, Durham, North Carolina NC 27713 or by phoning (919) 361-2286. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Avicin Therapeutics Ltd |
| Contact Person: | Daniel Cato |
| Address: | 4364 South Alston Avenue, Durham, North Carolina 27713 |
| Phone Number: | (919) 361-2286 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Avicin Therapeutics Ltd was started in 2013 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Daniel Cato for inquiries that concern Avicin Therapeutics Ltd by calling the company number (919) 361-2286, as your correspondence is most welcome. Additionally, the physical location of the single location of Avicin Therapeutics Ltd can be found at the coordinates 35.906368,-78.888838 as well as the street address 4364 South Alston Avenue in Durham, North Carolina 27713.
For its online presence, you may visit Avicin Therapeutics Ltd’s website at and engage with its social media outlets through on Twitter and on Facebook.